XML 150 R77.htm IDEA: XBRL DOCUMENT v3.22.4
Segmentation of key figures - Net sales by region (Details 7) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Disclosure of operating segments [line items]      
Net sales to third parties $ 50,545 $ 51,626 $ 48,659
Change to prior year-end [member]      
Disclosure of operating segments [line items]      
Net sales, change in % (2.00%) 6.00%  
Europe [member]      
Disclosure of operating segments [line items]      
Net sales to third parties $ 18,467 $ 20,197 18,715
Europe [member] | Change to prior year-end [member]      
Disclosure of operating segments [line items]      
Net sales, change in % (9.00%) 8.00%  
US      
Disclosure of operating segments [line items]      
Net sales to third parties $ 17,653 $ 16,818 16,484
US | Change to prior year-end [member]      
Disclosure of operating segments [line items]      
Net sales, change in % 5.00% 2.00%  
Asia/Africa/Australasia [member]      
Disclosure of operating segments [line items]      
Net sales to third parties $ 10,542 $ 10,966 10,219
Asia/Africa/Australasia [member] | Change to prior year-end [member]      
Disclosure of operating segments [line items]      
Net sales, change in % (4.00%) 7.00%  
Canada and Latin America [member]      
Disclosure of operating segments [line items]      
Net sales to third parties $ 3,883 $ 3,645 3,241
Canada and Latin America [member] | Change to prior year-end [member]      
Disclosure of operating segments [line items]      
Net sales, change in % 7.00% 12.00%  
Established Markets [member]      
Disclosure of operating segments [line items]      
Net sales to third parties $ 37,008 $ 38,314 36,732
Established Markets [member] | Change to prior year-end [member]      
Disclosure of operating segments [line items]      
Net sales, change in % (3.00%) 4.00%  
Emerging Growth Markets [member]      
Disclosure of operating segments [line items]      
Net sales to third parties $ 13,537 $ 13,312 11,927
Emerging Growth Markets [member] | Change to prior year-end [member]      
Disclosure of operating segments [line items]      
Net sales, change in % 2.00% 12.00%  
Innovative Medicines      
Disclosure of operating segments [line items]      
Net sales to third parties $ 41,296 $ 41,995 39,013
Innovative Medicines | Change to prior year-end [member]      
Disclosure of operating segments [line items]      
Net sales, change in % (2.00%) 8.00%  
Innovative Medicines | Europe [member]      
Disclosure of operating segments [line items]      
Net sales to third parties $ 13,554 $ 14,919 13,484
Innovative Medicines | Europe [member] | Change to prior year-end [member]      
Disclosure of operating segments [line items]      
Net sales, change in % (9.00%) 11.00%  
Innovative Medicines | US      
Disclosure of operating segments [line items]      
Net sales to third parties $ 15,899 $ 14,999 14,342
Innovative Medicines | US | Change to prior year-end [member]      
Disclosure of operating segments [line items]      
Net sales, change in % 6.00% 5.00%  
Innovative Medicines | Asia/Africa/Australasia [member]      
Disclosure of operating segments [line items]      
Net sales to third parties $ 8,929 $ 9,304 8,718
Innovative Medicines | Asia/Africa/Australasia [member] | Change to prior year-end [member]      
Disclosure of operating segments [line items]      
Net sales, change in % (4.00%) 7.00%  
Innovative Medicines | Canada and Latin America [member]      
Disclosure of operating segments [line items]      
Net sales to third parties $ 2,914 $ 2,773 2,469
Innovative Medicines | Canada and Latin America [member] | Change to prior year-end [member]      
Disclosure of operating segments [line items]      
Net sales, change in % 5.00% 12.00%  
Innovative Medicines | Established Markets [member]      
Disclosure of operating segments [line items]      
Net sales to third parties $ 30,548 $ 31,459 29,643
Innovative Medicines | Established Markets [member] | Change to prior year-end [member]      
Disclosure of operating segments [line items]      
Net sales, change in % (3.00%) 6.00%  
Innovative Medicines | Emerging Growth Markets [member]      
Disclosure of operating segments [line items]      
Net sales to third parties $ 10,748 $ 10,536 9,370
Innovative Medicines | Emerging Growth Markets [member] | Change to prior year-end [member]      
Disclosure of operating segments [line items]      
Net sales, change in % 2.00% 12.00%  
Sandoz      
Disclosure of operating segments [line items]      
Net sales to third parties $ 9,249 $ 9,631 9,646
Net sales, change in % (4.00%) 0.00%  
Sandoz | Change to prior year-end [member]      
Disclosure of operating segments [line items]      
Net sales, change in % (4.00%) 0.00%  
Sandoz | Europe [member]      
Disclosure of operating segments [line items]      
Net sales to third parties $ 4,913 $ 5,278 5,231
Sandoz | Europe [member] | Change to prior year-end [member]      
Disclosure of operating segments [line items]      
Net sales, change in % (7.00%) 1.00%  
Sandoz | US      
Disclosure of operating segments [line items]      
Net sales to third parties $ 1,754 $ 1,819 2,142
Sandoz | US | Change to prior year-end [member]      
Disclosure of operating segments [line items]      
Net sales, change in % (4.00%) (15.00%)  
Sandoz | Asia/Africa/Australasia [member]      
Disclosure of operating segments [line items]      
Net sales to third parties $ 1,613 $ 1,662 1,501
Sandoz | Asia/Africa/Australasia [member] | Change to prior year-end [member]      
Disclosure of operating segments [line items]      
Net sales, change in % (3.00%) 11.00%  
Sandoz | Canada and Latin America [member]      
Disclosure of operating segments [line items]      
Net sales to third parties $ 969 $ 872 772
Sandoz | Canada and Latin America [member] | Change to prior year-end [member]      
Disclosure of operating segments [line items]      
Net sales, change in % 11.00% 13.00%  
Sandoz | Established Markets [member]      
Disclosure of operating segments [line items]      
Net sales to third parties $ 6,460 $ 6,855 7,089
Sandoz | Established Markets [member] | Change to prior year-end [member]      
Disclosure of operating segments [line items]      
Net sales, change in % (6.00%) (3.00%)  
Sandoz | Emerging Growth Markets [member]      
Disclosure of operating segments [line items]      
Net sales to third parties $ 2,789 $ 2,776 $ 2,557
Sandoz | Emerging Growth Markets [member] | Change to prior year-end [member]      
Disclosure of operating segments [line items]      
Net sales, change in % 0.00% 9.00%  
Operating segments [member] | Innovative Medicines      
Disclosure of operating segments [line items]      
Net sales, change in % (2.00%) 8.00%